GR900100372A - Προιον ζευξεως πολυπεπτιδιου-αντισωματος για την παρεμποδιση τησπροσφυσεως κυτταρων. - Google Patents

Προιον ζευξεως πολυπεπτιδιου-αντισωματος για την παρεμποδιση τησπροσφυσεως κυτταρων.

Info

Publication number
GR900100372A
GR900100372A GR900100372A GR900100372A GR900100372A GR 900100372 A GR900100372 A GR 900100372A GR 900100372 A GR900100372 A GR 900100372A GR 900100372 A GR900100372 A GR 900100372A GR 900100372 A GR900100372 A GR 900100372A
Authority
GR
Greece
Prior art keywords
product
cytraphy
intervention
offers
manufacturing
Prior art date
Application number
GR900100372A
Other languages
English (en)
Inventor
A David Cheresh
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Publication of GR900100372A publication Critical patent/GR900100372A/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Περιγράφεται προϊόν ζεύξεως πολυπεπτιδίου-αντισώματος περιέχον πολυπεπτίδιον δεσμεύον την ιντεγκρίνην συνδεόμενον λειτουργικώς προς μόριον αντισώματος το οποίον ανοσο-αντιδρά μετά αντιγόνου της επιφανείας συγκολλητικών κυττάρων. Περιγράφονται επίσης θεραπευτικαί συνθέσεις και μέθοδοι χρησιμοποιήσεως των τοιούτων συνθέσεων κατά τας οποίας το προϊόν ζεύξεως πολυπεπτιδίου-αντισώματος δύναται να χρησιμοποιηθεί προς παρεμπόδισιν της συγκολήσεως κυττάρων εις φαινόμενα εξαρτώμενα εκ της συγκολλήσεως ως είναι η ανάπτυξις όγκων και η συσσωμάτωσις αιμοπεταλίων. ω
GR900100372A 1989-05-17 1990-05-16 Προιον ζευξεως πολυπεπτιδιου-αντισωματος για την παρεμποδιση τησπροσφυσεως κυτταρων. GR900100372A (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36261789A 1989-05-17 1989-05-17

Publications (1)

Publication Number Publication Date
GR900100372A true GR900100372A (el) 1991-10-10

Family

ID=23426812

Family Applications (1)

Application Number Title Priority Date Filing Date
GR900100372A GR900100372A (el) 1989-05-17 1990-05-16 Προιον ζευξεως πολυπεπτιδιου-αντισωματος για την παρεμποδιση τησπροσφυσεως κυτταρων.

Country Status (6)

Country Link
AU (1) AU5815990A (el)
CA (1) CA2016962A1 (el)
GR (1) GR900100372A (el)
IE (1) IE901736L (el)
PT (1) PT94067A (el)
WO (1) WO1990014103A1 (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5612311A (en) * 1990-04-06 1997-03-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
JP3283041B2 (ja) * 1990-07-13 2002-05-20 学校法人藤田学園 人工抗体
JPH06507641A (ja) * 1991-05-03 1994-09-01 ザ ロックフェラー ユニバーシティ 白血球ｃｒ３に対する内皮細胞リガンド認識抗体
WO1994009034A1 (en) * 1992-10-12 1994-04-28 Agen Limited Clot directed anticoagulant, process for making same and methods of use
US6180134B1 (en) 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
ATE235513T1 (de) * 1997-11-07 2003-04-15 Conjuchem Inc Opioid-konjugate mit endogenen trägerproteinen
CN1399554A (zh) * 1999-09-23 2003-02-26 斯克里普斯研究学院 抑制粘连形成的方法和组合物
CA2405469C (en) 2000-04-12 2012-03-20 Amersham Health As Integrin binding peptide derivatives
NO20004795D0 (no) 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
BRPI0210886B8 (pt) 2001-07-10 2021-05-25 Amersham Health As composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
US20110256055A1 (en) 2008-12-23 2011-10-20 Ge Healthcare Limited Application of 99mtc peptide-based compound as a bone marrow imaging agent
WO2011112549A2 (en) * 2010-03-10 2011-09-15 Emory University Temperature sensitive conjugate compositions, and uses related thereto

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0088695A2 (en) * 1982-03-09 1983-09-14 Cytogen Corporation Antibody conjugates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
AU573529B2 (en) * 1982-05-12 1988-06-16 President And Fellows Of Harvard College Hybrid proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0088695A2 (en) * 1982-03-09 1983-09-14 Cytogen Corporation Antibody conjugates

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 71, no. 4, April 1988, pages 831-843, New York, US; D.R. PHILLIPS et al.: "Review article: The platelet membrane glycoprotein IIb-IIIa complex" *
CLAIMS NOT SEARCHED: 12-14 *
CLAIMS SEARCHED: 1-11 *
EXPERIMENTAL CELL RESEARCH, vol. 182, 8th May 1989, pages 186-196, New York, US; Y.N. DANILOV et al.: "(Arg-Gly-Asp)-albumin conjugates as a model substratum for integrin-mediated cell adhesion" *
SCIENCE, vol. 238, 1987, pages 1132-1134, Washington, DC, US; Y. IWAMOTO et al.: "YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation" *
THE JOURNAL OF CELLULAR BIOLOGY, vol. 104, no. 3, March 1987, pages 573-584, New York, US; I.I. SINGER et al.: "The fibronectin cell attachment sequence Arg-Gly-Asp-Ser promotes focal contact formation during early fibroblast attachment and spreading" *
THE JOURNAL OF CELLULAR BIOLOGY, vol. 106, no. 3, March 1988, pages 925-930, New York, US; K.R. GEHLSEN et al.: "Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides" *

Also Published As

Publication number Publication date
IE901736L (en) 1990-11-17
PT94067A (pt) 1991-02-08
AU5815990A (en) 1990-12-18
CA2016962A1 (en) 1990-11-17
WO1990014103A1 (en) 1990-11-29

Similar Documents

Publication Publication Date Title
GR900100372A (el) Προιον ζευξεως πολυπεπτιδιου-αντισωματος για την παρεμποδιση τησπροσφυσεως κυτταρων.
DK499086A (da) Konjugater af trichothecen og anvendelse af samme som terapeutisk substans
DK0412486T3 (da) Antistoffer mod TNF-bindingsprotein I og F(ab)-fragmenter
DE3889340D1 (de) Verbreitung von arzneimittelsystemen.
GR1000247B (el) Σταθεραι λυοφιλιωμεναι διαμορφωσεις περιεχουσαι παραγοντας αναπτυξεως.
GR1000477B (el) Νεο μονοκλωνικο αντισωμα κατα νεου αντιγονου που σχετιζεται με ανθρωπινους ογκους.
ATE218143T1 (de) Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität
DK0554344T3 (da) Farmaceutisk præparat til behandling eller forebyggelse af en malign tumor
DK121683D0 (da) Fremgangsmade til fremstilling af immunoenzymatiske konjugater
AU2894289A (en) Domain-modified constant region antibodies
ES2027377T3 (es) Una mezcla polimerica adecuada para ser utilizada en pelicula o lamina de evasado.
EP0247730A3 (en) Antibodies, their preparation and use and products containing them
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
DK549188D0 (da) Lymfocythaemmende hla-peptider
ES2141249T3 (es) Procedimiento para la identificacion de celulas humanas y animales que presentan la capacidad para una proliferacion ilimitada o para una formacion de tumores.
DE69317886D1 (de) Neue propoxyphenderivate sowie deren protein-und polypeptidlabels und-konjugate
ES2150443T3 (es) Derivados de benzodiazepina y conjugados proteicos y polipeptidicos de los indicados derivados.
ES2063200T3 (es) Conjugados proteicos magneticos, procedimiento para su preparacion y su empleo.
CA2133838A1 (en) Immunotoxins directed against cd33 related surface antigens
ATE90790T1 (de) Verfahren zur herstellung einer festphasenmatrix.
AU576088B2 (en) Histamine derivatives, immunogen conjugates and antibodies raised thereto
IT1061215B (it) Procedimento per produrre giunti incollati nella rilegatura di libri e cosi rilegati
DE69611037D1 (de) Methadonderivate und protein- und polypeptid-methadonkonjugate und markierte verbindungen
GR900100550A (el) Μία μέ?οδος για την αναστολή της αντιγραφής ιού σε κύτταρα ?ηλαστικών χρησιμοποιώντας συζυγείς πρωτεϊνης αντιιού φυτολάκκας - μονοκλωνικού αντισώματος.
FI894551A7 (fi) Hybridiset monoklonaaliset vasta-aineet, niiden valmistus ja käyttö